Open Government Portal

Found 10 records similar to Draft Guidance for Industry: Preparation of Comparative Bioavailability Information for Drug Submissions in the CTD Format

Federal

This Guidance Document is to be used in the preparation of Veterinary Drug Submissions for presentation to Health Canada. Some sections of this Guidance Document are general in nature. Therefore, this Guidance Document should be used in conjunction with the complete Food and Drugs Act and Regulations, and with specific Health Canada Policies and Guidance Documents applicable to veterinary drugs.

Last Updated: Jul. 8, 2021
Date Published: Mar. 2, 2007
Organization: Health Canada
Formats: HTML
Keywords:  Guidance for industry, veterinary new drug submissions, preparation of veterinary new drug submissions, Food and Drugs Act and Regulations, policies on veterinary drugs.
Federal

To ensure that sponsors of new drug submissions have the information necessary to comply with Sections C.08.002(2)(h), C.08.002.1(2)(c)(ii) and C.08.003(3) of the Food and Drug Regulations with respect to comparative bioavailability and comparative pharmacodynamic studies used in support of the safety and efficacy of a drug.

Last Updated: Jun. 1, 2021
Date Published: Mar. 1, 2018
Organization: Health Canada
Formats: HTML
Keywords:  guidance document, comparative bioavailability standards, comparative pharmacodynamic studies, Food and Drug Regulations, safety of a drug
Federal

To provide sponsors of new drug submissions with the information necessary to comply with Sections C.08.002(2)(h), C.08.002.1(2)(c)(ii) and C.08.003(3) of the Food and Drug Regulations (Regulations) with respect to comparative bioavailability studies used in support of the safety and efficacy of a drug.

Last Updated: Jun. 1, 2021
Date Published: Sep. 1, 2018
Organization: Health Canada
Formats: HTML
Keywords:  guidance document, conduct and analysis, comparative bioavailability studies, pharmaceutically equivalent, data requirements and criteria
Federal

This guidance document is intended to provide sponsors with an outline of the chemistry and manufacturing, clinical, and human safety requirements for the filing of the following submission types with the Veterinary Drugs Directorate (VDD): Abbreviated New Drug Submission (ANDS); Changes to ANDS - Supplemental Abbreviated New Drug Submission (SANDS) and Notifiable Change (NC).

Last Updated: Jul. 8, 2021
Date Published: Feb. 8, 2010
Organization: Health Canada
Formats: HTML
Keywords:  Guidance for industry, veterinary abbreviated new drug submissions, preparation of veterinary abbreviated new drug submissions, supplemental abbreviated new drug submission, notifiable change, generic drugs, chemistry and manufacturing, clinical, and human safety requirements
Federal

Health Canada is issuing this guidance for clinical trials in type 2 diabetes to provide clarification on the interpretation of the Canadian Diabetes Association Clinical Practice Guidelines (CDA-CPG)Footnote1 in relation to clinical trial applications under Part C, Division 5 of the Food and Drug Regulations.

Last Updated: Jun. 2, 2021
Date Published: Sep. 4, 2007
Organization: Health Canada
Formats: HTML
Keywords:  guidance for industry, standards, clinical trials in type 2 diabetes, Canadian Diabetes Association Clinical Practice Guidelines, CDA-CPG, Food and drug Regulations
Federal

This guidance aims to articulate Health Canada's expectations and generate a level of consistency regarding the interpretation of the Priority Review of Drug Submissions policy and the filing of a Priority Review request. Additional clarification of the process by which the Priority Review request is assessed is provided.

Last Updated: Jul. 7, 2021
Date Published: Jul. 6, 2012
Organization: Health Canada
Formats: HTML
Keywords:  Guidance for industry, priority review of drug submissions, interpretation of the priority review of drug submissions policy, priority review request
Federal

The Guidance Document: Management of Drug Submissions and Applications (MDSG) gives sponsors and Health Canada staff operational direction and guidance when managing information submitted in accordance with the Food and Drugs Act and its Regulations.

Last Updated: Jul. 7, 2021
Date Published: May 26, 2021
Organization: Health Canada
Formats: HTML
Keywords:  Guidance document, management of drug submissions and applications, sponsors, operational direction, managing information submitted during drug submissions and applications
Federal

The purpose of this document is to provide sponsors of new drug submissions and abbreviated new drug submissions with the information necessary to comply with Sections C.08.002(2)(h), C.08.002.1(2)(c)(ii) and C.08.003(3) of the Food and Drug Regulations, with respect to comparative pharmacokinetic studies, with emphasis on in vivo comparative pharmacokinetic studies.

Last Updated: Jun. 2, 2021
Date Published: Feb. 27, 2020
Organization: Health Canada
Formats: HTML
Keywords:  draft guidance, consultation, comparative pharmacokinetic studies, orally inhaled products, sponsors of new drug submissions, abbreviated new drug submissions, Food and Drug Regulations
Federal

This guidance document provides clarification to submission sponsors on how to comply with (Veterinary Drugs Directorate of Health Canada) VDD's policies, governing statutes and regulations.

Last Updated: Jul. 8, 2021
Date Published: Nov. 6, 2009
Organization: Health Canada
Formats: HTML
Keywords:  Guidance document, industry, sponsors, management of regulatory submissions, Veterinary Drugs Directorate of Health Canada, VDD, VDD's policies
Federal

Health Canada is revising the Guidance Document entitled: The Management of Drug Submissions and Applications (MDSA). This document provides sponsors and Health Canada staff of the Therapeutic Products Directorate, the Biologic and Radiopharmaceutical Drugs Directorate, the Natural and Non-Prescription Health Products Directorate (Non-Prescription Drugs Evaluation Division), and the Marketed Health Products Directorate with operational direction and guidance regarding the way in which drug submissions, applications or post-market documents submitted to Health Canada are managed.

Last Updated: Dec. 29, 2021
Date Published: Jul. 7, 2021
Organization: Health Canada
Formats: HTML
Keywords:  revising guidance document, drug submissions, drug applications, post-market documents submissions, operational direction
Date modified: